Diabetes Treatments Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Diabetes Treatments Market size was estimated at USD 82.7 billion in 2023 and is projected to reach USD 156.2 billion in 2030 at a CAGR of 5.0% during the forecast period 2024-2030.

The global diabetes treatment market is a dynamic sector driven by the prevalence of diabetes mellitus, a metabolic disorder characterized by elevated blood sugar levels due to insufficient insulin production or improper cell response to insulin. This chronic condition affects millions worldwide and necessitates a comprehensive market for managing and treating its symptoms effectively.

Key drivers of market growth include the escalating incidence of obesity, a significant risk factor for type 2 diabetes. As obesity rates rise globally, so does the prevalence of diabetes, fueling demand for advanced treatment options. Technological advancements play a pivotal role, with continuous glucose monitoring systems and innovative insulin delivery devices revolutionizing diabetes management. These technologies offer precise and individualized solutions, marking a shift towards personalized medicine in diabetes care.

Government initiatives also contribute significantly to market expansion. The World Health Organization's Global Action Plan for Noncommunicable Diseases underscores diabetes prevention, screening, and treatment as key priorities. Governments worldwide are implementing policies and programs to enhance healthcare infrastructure and improve access to diabetes management resources.

Despite growth drivers, the diabetes treatment market faces challenges. High treatment costs and inadequate reimbursement policies hinder market potential, posing financial barriers for patients and healthcare providers alike. Addressing these challenges is crucial to unlocking the full market potential and ensuring equitable access to effective diabetes care.

Demographic shifts, including an aging population and lifestyle changes, further influence market dynamics. Collaborative efforts among governments, healthcare professionals, and industry stakeholders aim to enhance early diagnosis, expand treatment access, and mitigate the economic burden of diabetes-related complications.

Major participants in the diabetes treatment market include medical device manufacturers, pharmaceutical companies, and healthcare service providers. These stakeholders drive market expansion through strategic alliances, product innovations, and regulatory compliance efforts. Regulatory agencies play a critical role in ensuring the safety and efficacy of diabetes treatments through stringent approval processes and post-market surveillance.

In conclusion, the diabetes treatment market encompasses a diverse range of medications, devices, and services aimed at managing blood sugar levels, preventing complications, and improving overall quality of life for individuals with diabetes. Despite challenges, ongoing advancements in technology and concerted global efforts are expected to sustain market growth, addressing the evolving needs of diabetes care worldwide.

Delvens Industry Expert's Standpoint

The Diabetes Treatment Market currently demonstrates robust growth driven by a combination of increasing prevalence of diabetes worldwide and advancements in treatment technologies. Factors such as rising obesity rates, sedentary lifestyles, and aging populations contribute to the escalating incidence of diabetes, necessitating expanded healthcare solutions. Technological innovations in continuous glucose monitoring systems, insulin delivery devices, and diabetes management software are enhancing treatment efficacy and patient outcomes, fostering market expansion.

Looking forward, the market is poised for continued growth as healthcare systems globally prioritize diabetes prevention, screening, and treatment. Government initiatives, including funding for diabetes research and healthcare infrastructure, play a pivotal role in shaping market dynamics. Regulatory frameworks and policies aimed at improving access to diabetes care and managing treatment costs will also influence market trend.

Market Portfolio

Key Findings

• On the basis of Drug Class, the insulin segment is poised for substantial growth in the global diabetes treatment market, driven by increasing demand from both Type-1 and some Type-2 diabetes patients, surpassing 30 million people as of 2020. Greater awareness of insulin's benefits, especially in emerging economies, along with advancements in insulin delivery methods and analog research, are key factors fueling market expansion. Additionally, the SGLT2 segment is expected to gain traction due to recent advancements in treating Type-1 diabetes, offering effective blood sugar management with fewer reported side effects, bolstering its market appeal alongside dietary measures.

• On the basis of Diabetes Type, Type 2 diabetes affects the majority of individuals with diabetes, characterized by the body's reduced ability to effectively use insulin, known as insulin resistance. As Type 2 diabetes progresses, insulin production by the pancreas may decline. Concurrently, Type 1 diabetes cases are also increasing, contributing to market revenue. Recent reports indicate approximately 1.6 million Americans, including 150,000 youth, have Type 1 diabetes, with around 61,000 new cases annually. This rising prevalence, coupled with limited research and treatment options in the segment, drives growth in the Type 1 diabetes market segment.

• On the basis of Distribution, the hospital pharmacies segment is anticipated to lead the global diabetes treatment market during the forecast period, driven by their extensive infrastructure, professional expertise, and comprehensive medication availability. Hospitals attract a large patient base due to their reputation for reliable medical services and skilled healthcare professionals, further bolstering their pharmacy offerings. Similarly, the retail segment is poised for significant growth, supported by the expansion of retail pharmacy networks globally and increasing availability of diabetes care products. Additionally, the online segment is expected to rise due to growing demand for personalized healthcare solutions and the widespread adoption of digital platforms, facilitating convenient access to diabetes management equipment and medications for home use.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America held the largest Diabetes Treatments Market share, driven by prominent industry players, substantial disposable income, extensive healthcare spending, and a well-established healthcare infrastructure. These factors collectively contribute to the region's dominance in advancing diabetes care and treatment innovations.

Regional Analysis

North America to Dominate the Market

• North America holds a substantial share of the global diabetes treatment market and is projected to grow at a promising compound annual growth rate (CAGR) in the coming years. Within North America, the United States leads in diabetes treatment. High insulin prices in the U.S., among the highest globally, have prompted patients to seek longer usage of insulin and explore more affordable options such as human insulin. This trend is expected to drive a decline in insulin prices in the near future, aiming to enhance affordability and accessibility of diabetes treatment options across the region.

Competitive Landscape

• Roche Products Limited
• Johnson & Johnson Services, Inc.
• Sanofi-Deutschland GmbH
• Novo Nordisk A/S
• ARKRAY USA, Inc.
• Bayer AG
• Amylin Pharmaceuticals Inc.
• Abbott
• Medtronic Inc.
• Teva Pharmaceuticals Pvt Ltd.
• Home Diagnostics Inc.
• Novartis AG
• Eli Lilly and Company.
• Merck & Co., Inc
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Takeda Pharmaceutical Company Limited

Recent Developments

• In October 2022, Novo Nordisk intends to seek regulatory approval for once-weekly insulin icodec, positioning it as a potential leading treatment for type 2 diabetes. The pharmaceutical firm plans to submit applications in the US, EU, and China by mid-2023 following positive results from the ONWARDS 5 phase 3a trial comparing it to once-daily basal insulin over 52 weeks.

• In May 2022, Novo Nordisk plans to invest around USD 98 million to modernize and expand its insulin production facility located in Kalundborg, Denmark.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
   
• Gain authentic and granular data access for the Diabetes Treatments Market to understand the trends and the factors involved in changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope